BioPharma Credit PLC Stock

Equities

BPCP

GB00BDGKMY29

Closed End Funds

Real-time Estimate Cboe Europe 10:58:48 2024-07-18 am EDT 5-day change 1st Jan Change
0.875 USD +0.11% Intraday chart for BioPharma Credit PLC +0.80% +4.40%
Sales 2022 218M Sales 2023 136M Capitalization 1.09B
Net income 2022 182M Net income 2023 108M EV / Sales 2022 5.19 x
Net cash position 2022 121M Net cash position 2023 135M EV / Sales 2023 7.07 x
P/E ratio 2022
7.11 x
P/E ratio 2023
10.1 x
Employees -
Yield 2022
7.37%
Yield 2023
8.33%
Free-Float 88.74%
More Fundamentals * Assessed data
Dynamic Chart
BioPharma Credit to Provide Additional Funding to LumiraDx Amid Roche Deal MT
BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ending 30 June 2024, Payable on 31 July 2024 CI
BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg MT
BioPharma Credit agrees USD400 million loan for oncology firm Novacure AN
BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals MT
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals AN
BioPharma Credit PLC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioPharma Credit net asset value ticks up but total payout lower AN
BioPharma Credit Board, Investment Manager Propose Changes to Discount Control Mechanism MT
BioPharma Credit Logs Lower FY23 Net Income Return on Ordinary Activities MT
Tranche Update on BioPharma Credit PLC's Equity Buyback Plan announced on May 31, 2023. CI
Biopharma Credit plc Declares Interim Dividend in Respect of the Financial Period Ending 31 March 2024, Payable on 30 April 2024 CI
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen MT
BioPharma Credit PLC Declares Interim Special Dividend in Respect of the Financial Period Ending 31 December 2023, Payable on 15 March 2024 CI
More news
1 day-0.09%
1 week+0.37%
Current month+3.95%
1 month+3.22%
3 months-0.32%
6 months-6.91%
Current year+3.95%
More quotes
1 week
0.86
Extreme 0.862
0.88
1 month
0.83
Extreme 0.83
0.88
Current year
0.83
Extreme 0.83
0.94
1 year
0.81
Extreme 0.81
0.94
3 years
0.81
Extreme 0.81
1.05
5 years
0.70
Extreme 0.6995
1.06
10 years
0.70
Extreme 0.6995
1.13
More quotes
Managers TitleAgeSince
Chief Investment Officer - -
Members of the board TitleAgeSince
Chairman 67 17-02-26
Director/Board Member 68 -
Director/Board Member - 18-12-04
More insiders
Date Price Change Volume
24-07-18 0.877 +0.34% 1 492 406
24-07-17 0.874 +0.23% 668,859
24-07-16 0.872 +0.23% 406,241
24-07-15 0.87 0.00% 1,995,698
24-07-12 0.87 0.00% 2,673,587

Delayed Quote London S.E., July 18, 2024 at 07:32 am EDT

More quotes
BioPharma Credit PLC is a United Kingdom-based specialist debt investor to the life sciences industry. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. It seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products. The Company may also invest in equity issued by a life sciences company, acquired directly from the life sciences company or in the secondary market. It will seek to create a diversified portfolio of investments by investing across a range of different forms of debt assets issued by a variety of borrowers. It has two wholly owned subsidiaries: BPCR Limited Partnership and BPCR GP Limited. The Company holds a majority of its investments through its financing subsidiary, BPCR Limited Partnership. Its investment manager is Pharmakon Advisors, LP.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.874
Average target price
-
Consensus

Annual profits - Rate of surprise